Amgen Biosimilar And EYLEA Patent Dispute
Regeneron's stock drops as it loses bid to block Amgen's Eylea biosimilar
Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for blockbuster eye disease drug Eylea, the same judge has rejected the company’s attempt to block Amgen’s Eylea biosimilar.
Stocks to Watch. In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stands ...
Regeneron’s stock $REGN dipped about 4% on Tuesday following a loss in its legal battle with Amgen over competitors to its ...
A U.S. judge ruled that Regeneron Pharmaceuticals cannot immediately block U.S. sales of a proposed copy of its blockbuster ...
Regeneron sued Amgen in January, alleging that it was developing a biosimilar that violated key patent protections for Eylea.
Three new post-hoc analyses highlight EYLEA HD rapid and sustained fluid control and consistent safety profile over two years in patients with ...
The European Medicines Agency approved Afqlir and Opuviz to treat age-related macular degeneration while reiterating its ...
Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that ...
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback